Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Senseonics Holdings Inc. Is Rising Today

By Brian Feroldi - Apr 4, 2018 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump after the company receives some favorable commentary from a Wall Street analyst.

What happened

After receiving a buy rating and an upbeat price target from a Wall Street analyst, shares of Senseonics Holdings (SENS -2.65%), a small-cap medical device company focused on glucose-monitoring solutions for people with diabetes, jumped as much as 10% in afternoon trading on Wednesday. Shares were up 9% as of 3:05 p.m. EDT.

So what

Senseonics bulls can thank Christopher Pasquale from Guggenheim for today's jump. Pasquale reiterated his buy rating on the company's stock and also set a price target of $6 per share. That represents an almost exact double from yesterday's closing price of about $3 per share.

Traders responded to the bullish analyst note by bidding up the share price.

Businessman giving two thumbs up with money falling all around him.

Image source: Getty Images.

Now what

Senseonics shareholders have enjoyed a prosperous 2018 thus far. The company shored up its balance sheet in January by raising about $48 million through a convertible note offering. More recently, we learned that the Food and Drug Administration (FDA) voted unanimously that its Eversense system is safe, effective, and the benefits of its use outweigh the risks. When combined with today's positive analyst commentary, Sensonics' shares have jumped more than 25% since the start of the year. 

So is now a smart time to buy into Sensonics' growth story? That's a tougher call.

On the plus side, the 90-day wear time of the Eversense system will likely be attractive to many patients. On the negative side, the device is going to have a heck of a time challenging the current market leader Dexcom (DXCM -3.03%), even if it wins approval. After all, Dexcom just won FDA approval for its G6 system that can be worn for 10 days, communicate directly with a smartphone or smartwatch, and requires no finger sticks for calibration. It's hard to say whether or not the Eversense system will be able to effectively compete against those benefits.

I know firsthand just how hard it can be to successfully launch a medical device in the diabetes industry against an incumbent, so I continue to believe that skepticism is warranted. That's why I'll continue to track Senseonics' progress from the safety of the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
DXCM
$324.60 (-3.03%) $-10.14
Senseonics Holdings, Inc. Stock Quote
Senseonics Holdings, Inc.
SENS
$1.10 (-2.65%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.